In recent years, the traditional idea of cirrhotic patients being auto-anticoagulated due to the decreased synthesis of coagulation proteins has been reexamined. Through promising researches in the past decades, it was revealed that cirrhosis alters the whole part of hemostatic system including primary, secondary and fibrinolytic pathways, which results in patients having the risk of both thrombosis and bleeding. As the traditional ways of treating bleeding including administration of fresh frozen plasma have been questionable due to its side effects, new options like prothrombin complex concentrates, firbrinogen-rich cryoprecitipates and thrombopoietin receptor agonoists are the new options. Also, as thrombotic events in cirrhosis are apparent, anticoagulation therapy has been reconsidered as a treatment option. the traditional options such as vitamin K antagonists and heparin derivaties are still available, the recent advancement in dicrect oral anticoagulants may revolutionize the treatment apporach in cirrhotic patients with thrombotic tendency. Furthermore, a more individualized bleeding control such as whole blood transfusion and damage control resuscitation strategy are currently being explored as treatment options. Reevaluation and comprehension of conventional and new drugs can potentially improve patient care and outcomes as this thesis explores the medical interventions for hemostatic changes in cirrhotic patients.